Celgene slumps as Bristol-Myers shareholder resists merger


Shares of Celgene Corp dived 8 percent on Thursday after a major shareholder in Bristol-Myers Squibb Co came out against a $74 billion merger that would be the pharmaceutical world’s biggest ever takeover.